Clinical characteristics and outcomes of BCMA-targeted CAR-T cell recipients with COVID-19 during the Omicron wave: a retrospective study - Takeaways - MDSpire

Clinical characteristics and outcomes of BCMA-targeted CAR-T cell recipients with COVID-19 during the Omicron wave: a retrospective study

  • By

  • Haiqiong Zheng

  • Shi Han

  • Yijin Chen

  • Houli Zhao

  • Rongrong Chen

  • Qiqi Zhang

  • Delin Kong

  • Mingming Zhang

  • Yongxian Hu

  • He Huang

  • February 21, 2025

  • 0 min

Share

  • 1

    The study focused on BCMA-targeted CAR-T cell recipients with relapsed or refractory multiple myeloma during the Omicron COVID-19 wave.

  • 2

    Patients with multiple myeloma are more susceptible to severe COVID-19 due to immune dysfunction from the disease and its treatments.

  • 3

    The study included 49 patients, predominantly male, with a median age of 60 years and a high incidence of severe cytokine release syndrome.

  • 4

    Overall response rates to BCMA-targeted CAR-T therapy were high, with 98% achieving a response and 67.3% achieving complete remission.

  • 5

    The study aimed to analyze clinical characteristics, outcomes, and risk factors for COVID-19 in this vulnerable patient population.

Original Source(s)

Clinical characteristics and outcomes of BCMA-targeted CAR-T cell recipients with COVID-19 during the Omicron wave: a retrospective study

  • by Haiqiong Zheng, Shi Han, Yijin Chen, Houli Zhao, Rongrong Chen, Qiqi Zhang, Delin Kong, Mingming Zhang, Yongxian Hu, He Huang

  • February 21, 2025

Related Content

Bone marrow hemodilution assessment in multiple myeloma MRD by next generation flow cytometry - a mini review

Treatment Intensity in the Frontline Setting for Transplant-Ineligible Patients With Multiple Myeloma

The management of newly diagnosed transplant-ineligible multiple myeloma remains challenging, in part due to the complexity of treatment decisions for frail patients. Recent subgroup analyses provide insight into whether quadruplet therapy may offer advantages over triplet therapy in this population.

This Week’s CGT News: Lilly’s $7B In Vivo CAR-T Bet

Lilly moves to acquire Kelonia, plus gene therapy for deafness approved

  • April 27, 2026

  • 6 min